Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT07606937
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a CAR-T cell therapy made using an automated process for people with relapsed or refractory large B-cell lymphoma. The study will enroll 12 adults whose cancer has not responded to or returned after first-line treatment. Researchers will measure how many patients achieve remission and track side effects to see if this manufacturing method is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
axicabtagene ciloleucel (CAR-T cell therapy)
What this could lead to
If successful, this could offer a new, more consistent way to produce CAR-T cells for treating aggressive lymphoma that has returned after initial therapy.
What could go wrong
This is a very early phase 1 trial with only 12 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-••••
Contact
-
Shanghai Jiaotong University School of Medicine Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-••••
Contact
-
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510700, China
Contact
Contact Phone: •••-•••-••••
-
The Frist Affiliated Hospital of Soochow University
NOT_YET_RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-••••
Contact
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300000, China
Contact
Contact Phone: •••-•••-••••
-
West China Hospotal Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
Contact Phone: •••-•••-••••